A new review in Endocrine Reviews ↗, the field's flagship journal, argues that two peptide systems most clinicians treat as separate problems are dysregulated together in long COVID and chronic fatigue syndrome. One is GLP-1, the gut hormone behind Wegovy ↗ and Ozempic ↗. The other is orexin, a pair of brain peptides that control sleep, alertness, and metabolic balance. The review's pitch: stop chasing them in isolation. A combined framework may be what post-viral medicine has been missing.
The clinical context is grim. Post-acute sequelae of COVID-19, formally PASC, ballooned during the pandemic. Many of those patients also meet criteria for myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS), the most disabling form of post-viral disease. The phenotype that defines both is consistent: severe fatigue, post-exertional malaise (where mild activity sets patients back for days), unrefreshing sleep, neurocognitive impairment, and autonomic plus immune dysregulation. There are no FDA-approved therapies for either condition. Patient management is symptom-by-symptom.
The review's central observation is that the orexin system and the GLP-1 system regulate exactly the functions that break in long COVID. Orexin neurons, sitting in the lateral hypothalamus, drive wakefulness, glucose handling, neuroendocrine signaling, and stress responses through the HPA axis (the brain's stress-hormone loop). The authors describe the phenotypic overlap point by point: fatigue, sleep issues, impaired glucose metabolism, neuropsychiatric symptoms. Each maps onto what orexin dysfunction produces in animal models and rare human syndromes. The piece also flags that orexin expression and function are sexually dimorphic, meaning the system runs differently in male and female brains, and notes that long COVID disproportionately affects women.
GLP-1, on the other side, does more than slow gastric emptying. The review summarizes the off-target effects that have accumulated in the literature: protection of brain tissue, anti-inflammatory action, blood-vessel protection, immune modulation. Each is a domain where GLP-1 drug-class secondary benefits keep showing up in observational data. Cardiovascular. Kidney. Atrial fibrillation. Migraine. Now, the authors propose, post-viral disease.
Then comes the therapeutic move. Two drug classes already hit the proposed targets. GLP-1 receptor agonists are FDA-approved and prescribed at very high volume; the review names them as candidate therapies for PASC and ME/CFS specifically because their off-label biological profile is the one post-viral patients need. Drugs targeting the orexin system are also clinically available, mostly as orexin receptor antagonists for insomnia, with orexin agonists in development for narcolepsy. The framework suggests both directions are worth investigating, depending on whether an individual patient's orexin tone is too high or too low.
A platform note. Peptidemodel hosts cards for both systems: native GLP-1(7-36) amide ↗, the endogenous version of the hormone the Wegovy and Ozempic class mimics, and Exendin-4(4-39) ↗, the receptor-blocking fragment researchers use to confirm GLP-1 effects in animals. On the orexin side, OX2R-004 ↗ is the platform's hosted candidate against the orexin receptor 2 target. If the post-viral hypothesis attracts more design work, the GLP-1R ↗ and OX2R ↗ target pages are where it will land.
What this is not. This is not a clinical trial. No long COVID patient has been studied on a GLP-1 plus orexin combination. The review names a framework that could organize the next round of trials. It also lands in a moment when GLP-1 secondary benefits are being reported almost weekly, in domains as varied as kidney transplant survival, atrial fibrillation, and migraine. If post-viral disease is on that growing list, the underlying biology of why may be exactly what this review just laid out.